Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitors

This page shows the latest PCSK9 inhibitors news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

Latest news

  • Merck & Co's anacetrapib data fails to generate much excitement Merck & Co's anacetrapib data fails to generate much excitement

    contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

  • Merck & Co's anacetrapib rescued by positive phase III trial Merck & Co's anacetrapib rescued by positive phase III trial

    cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density

  • Repatha outcomes data Repatha outcomes data "less than stellar"

    than stellar." Investors are now more cautious on prospects for PCSK9 inhibitors as a result, he suggested in a research note. ... It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also

  • Praluent can stay on market for now, says US court Praluent can stay on market for now, says US court

    Both drugs are PCSK9 inhibitors that have been approved in the US to help patients who cannot meet their cholesterol targets with existing therapy, such as statin drugs, or who have ... Praluent was approved in the US first, but Amgen has so far won the

  • Choose or lose Choose or lose

    Without evidence that they can reduce atherosclerotic plaques, Amgen and Sanofi know that PCSK9 inhibitors will struggle to get their expensive price.

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics